Cargando…

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment

BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective for advanced non‐small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasahara, Norimitsu, Imai, Hisao, Naruse, Ichiro, Tsukagoshi, Yusuke, Kotake, Mie, Sunaga, Noriaki, Kaira, Kyoichi, Maeno, Toshitaka, Asao, Takayuki, Hisada, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396379/ https://www.ncbi.nlm.nih.gov/pubmed/32495520 http://dx.doi.org/10.1111/1759-7714.13526

Ejemplares similares

The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome
por: Hachisu, Yoshimasa, et al.
Publicado: (2017)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors
por: Imai, Hisao, et al.
Publicado: (2019)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study
por: Kotake, Mie, et al.
Publicado: (2019)

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors
por: Miura, Yosuke, et al.
Publicado: (2017)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga, Noriaki, et al.
Publicado: (2015)

Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients
por: Hachisu, Yoshimasa, et al.
Publicado: (2019)

The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis
por: Hachisu, Yoshimasa, et al.
Publicado: (2022)

Small-cell lung cancer with voltage-gated calcium channel antibody-positive paraneoplastic limbic encephalitis: a case report
por: Kaira, Kyoichi, et al.
Publicado: (2014)

Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis
por: Sunaga, Noriaki, et al.
Publicado: (2022)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis
por: Imai, Hisao, et al.
Publicado: (2018)

Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature
por: Saito, Yasuyuki, et al.
Publicado: (2017)

Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis
por: Imai, Hisao, et al.
Publicado: (2020)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations
por: Imai, Hisao, et al.
Publicado: (2021)

Clinical significance of post‐progression survival in lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report
por: Yanagitani, Noriko, et al.
Publicado: (2009)

The role of [(18)F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors
por: Kaira, Kyoichi, et al.
Publicado: (2011)

Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non–small-cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2019)

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021)

Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
por: Tsukagoshi, Mariko, et al.
Publicado: (2020)

Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study
por: Imai, Hisao, et al.
Publicado: (2021)

A case of a patient with neurofibromatosis type I who developed pneumothorax and eosinophilic pleural effusion after suffering from COVID-19 pneumonia
por: Wakamatsu, Ikuo, et al.
Publicado: (2021)

Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

A pregnant woman with severe dyspnoea
por: Kanbe, Mio, et al.
Publicado: (2022)

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation
por: Sato, Mari, et al.
Publicado: (2023)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
por: Kasahara, Norimitsu, et al.
Publicado: (2015)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
por: Wasamoto, Satoshi, et al.
Publicado: (2023)

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
por: Kunimasa, Kei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fej7vhbahphjgrg0i0ep21cuoh